ViiV Healthcare is an independent, global specialist HIV company dedicated to delivering innovative new options for the care and treatment of people living with HIV/AIDS.
Established in 2009 through a unique partnership between GSK and Pfizer, the company now combines the HIV expertise of both companies and Shionogi, who joined in 2012 following a long-term collaboration on the joint development of several novel integrase inhibitors.
Our current portfolio of twelve HIV treatments generated annual sales of £2.3 billion in 2015 providing us with the financial stability to take a sustainable, long-term view when investing in our pipeline of new medicines. Our scientists are 100% dedicated to finding new ways to limit the impact of HIV on the 36.9 million people living with the virus and understanding how best to prevent and treat the disease. Find out more about our commitment to R&D in the ViiV homepage.
Our dedicated staff of almost 700 people are located in 15 countries and three regional hubs, and we extend this geographical reach still further because of the relationship between ViiV Healthcare and GSK. Hong Kong, one of the most accessible and advanced cities in Asia, is home to the regional hub of ViiV Healthcare in Asia Pacific.
We are equipped to move quickly in response to the needs of the HIV community and have launched industry-leading access initiatives to help deliver on WHO/UNAIDS goals to reach all those who need treatment. Find out more about our innovative and sustainable approach to access in the ViiV homepage.
In addition, we actively support community initiatives in HIV, including the Positive Action programme, by partnering with like-minded organisations that share our ethos.